CDx Pipeline Tracking
Automated tracking of all CDx approvals, partnerships, and clinical trial biomarker strategies across 100+ indications.
Precision Diagnostics
Intelligence for the Precision Diagnostics Ecosystem
Six companies are locked in intense competition across MRD, CDx, MCED, and liquid biopsy — creating the highest-demand segment for competitive intelligence in the bio-venture ecosystem.
Diagnostic Market Segments
The precision diagnostics value chain spans multiple high-growth segments, each with distinct competitive dynamics.
Critical
Companion Diagnostics (CDx)
FDA-approved CDx indications have grown from ~20 in 2018 to 100+ in 2025, with ADC biomarker requirements accelerating demand further.
$12B+Market by 2030
Critical
Liquid Biopsy
Blood-based testing for cancer detection, treatment selection, and monitoring. Multiple competing platforms across ctDNA, methylation, and proteomics.
$8B+Market by 2028
High
MRD Monitoring
Minimal residual disease testing for treatment response monitoring. Intense competition between SNP-based, ctDNA, and tissue-informed approaches.
$3-5BEmerging opportunity
High
Multi-Cancer Early Detection
Population-level cancer screening through blood tests. Uncertain FDA/CMS coverage pathways create complex regulatory modeling requirements.
$50B+If validated at scale
Medium
Molecular Profiling
Comprehensive genomic profiling for treatment selection. Growing from oncology into immunology, rare disease, and cardiology applications.
65%+Oncology trials biomarker-driven
Medium
AI-Powered Insights
Clinical and molecular datasets powering AI-driven diagnostic insights, drug discovery, and real-world evidence generation.
40M+De-identified records
Capabilities
How We Help Diagnostics Companies
Purpose-built intelligence for companies operating at the intersection of diagnostic data and therapeutic decision-making.
Partnership Intelligence
Identify the most valuable pharma CDx partnership opportunities before competitors. Monitor pipeline decisions that drive CDx demand.
Regulatory Modeling
Simulate FDA/CMS parallel review processes and coverage decisions. Optimize CDx submission timing to align with drug sponsor timelines.
Market Entry War-Gaming
Model optimal launch sequencing for MRD and MCED products in crowded markets with multiple competing technologies.
Trial Design Optimization
Design biomarker-enriched clinical trials that demonstrate assay clinical utility. 30-40% improvement in biomarker-positive patient identification.
Competitive Positioning
Real-time intelligence on competitor assay performance, clinical validation data, and commercial traction across all diagnostic segments.
The CDx landscape is evolving faster than manual methods can track
Get automated competitive intelligence across 100+ CDx indications. Deploy in 4-6 weeks.